Search results
Results from the WOW.Com Content Network
The following revised diagnostic criteria for essential thrombocythemia were proposed in 2005. [13] The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6. [14] The criteria are as follows: [14] A1. Platelet count > 400 × 10 3 /μL for at least 2 months. A2. Acquired V617F JAK2 ...
The SARS disease caused thrombocytosis. [10] Once the reactive causes of thrombocythemia are ruled out, clonal thrombocythemia should be considered. The most common cause of clonal thrombocythemia is a myeloproliferative neoplasm. These include: essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and primary ...
Each country has its own rules to protect the safety of both donor and recipient. In a typical set of rules, a platelet donor must weigh at least 50 kg (110 lb) and have a platelet count of at least 150 x 10 9 /L (150,000 platelets per mm³). [2] One unit has greater than 3×10 11 platelets. Therefore, it takes 2 liters of blood having a ...
Basophilia is the condition of having greater than 200 basophils/μL in the venous blood. [1] Basophils are the least numerous of the myelogenous cells, and it is rare for their numbers to be abnormally high without changes to other blood components.
Thrombocytosis (increase in the number of platelets) Myeloproliferative disorder; Transient myeloproliferative disease; Coagulopathies (disorders of bleeding and coagulation) Thrombocytosis; Recurrent thrombosis; Disseminated intravascular coagulation; Disorders of clotting proteins Hemophilia. Hemophilia A; Hemophilia B (also known as ...
This is a shortened version of the fourth chapter of the ICD-9: Diseases of the Blood and Blood-forming Organs. It covers ICD codes 280 to 289. The full chapter can be found on pages 167 to 175 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
Anagrelide is used to treat essential thrombocytosis, especially when the current treatment of the patient is insufficient. [4] Essential thrombocytosis patients who are suitable for anagrelide often meet one or more of the following factors: [5] [6] age over 60 years; platelet count over 1000×10 9 /L; a history of thrombosis
Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body. [2] This results in a low platelet count, low red blood cells due to their breakdown, and often kidney, heart, and brain dysfunction. [1]